Skip to main content
SpringerLink
Log in

The platelet activating factor acetyl hydrolase, oxidized low-density lipoprotein, paraoxonase 1 and arylesterase levels in treated and untreated patients with polycystic ovary syndrome

  • General Gynecology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the platelet activating factor acetyl hydrolyze (PAF-AH), oxidized low-density lipoprotein (ox-LDL), paraoxonase 1 (PON1), arylesterase (ARE) levels and the effects of metformin and Diane-35 (ethinyl oestradiol + cyproterone acetate) therapies on these parameters and to determine the PON1 polymorphisms among PCOS patients.

Methods

Ninety patients with PCOS, age 30, and body mass index-matched healthy controls were included in the study. Patients were divided into three groups: metformin treatment, Diane-35 treatment and no medication groups. The treatment with metformin or Diane-35 was continued for 6 months and all subjects were evaluated with clinical and biochemical parameters 6 months later. One-way Anova test, t test and non-parametric Mann–Whitney U tests were used for statistical analysis.

Results

PAF-AH and ox-LDL levels were statistically significantly higher in untreated PCOS patients than controls, and they were statistically significantly lower in patients treated with metformin or Diane-35 than untreated PCOS patients. In contrast, there were lower PON1 (not statistically significant) and ARE (statistically significant) levels in untreated PCOS patients than the control group and they significantly increased after metformin and Diane-35 treatments. In PCOS patients serum PON1 levels for QQ, QR and RR phenotypes were statistically significantly lower than the control group.

Conclusion

In patients with PCOS, proatherogenic markers increase. The treatment of PCOS with metformin or Diane-35 had positive effects on lipid profile, increased PON1 level, which is a protector from atherosclerosis and decreased the proatherogenic PAF-AH and ox-LDL levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Seow KM, Juan CC, Wang PH, Ho LT, Hwang JL (2012) Expression levels of vascular cell adhesion molecule-1 in young and nonobese women with polycystic ovary syndrome. Gynecol Obstet Investig 73(3):236–241

    Article  CAS  Google Scholar 

  2. Homburg R (2008) Polycystic ovary syndrome. Clin Obstet Gynaecol 2:261–274

    Google Scholar 

  3. Cussons AJ, Stuckey BG, Watts GF (2006) Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 185:227–239

    Article  PubMed  CAS  Google Scholar 

  4. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM (2002) The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 30(5):294–301

    Article  Google Scholar 

  5. Stafforini DM (2009) Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc Drugs Ther 23(1):73–83

    Article  PubMed  CAS  Google Scholar 

  6. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH (2000) Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150:413–419

    Article  PubMed  CAS  Google Scholar 

  7. Arai H (2014) Oxidative modification of lipoproteins. Subcell Biochem 77:103–114

    Article  PubMed  Google Scholar 

  8. Canales A, Sanchez-Munis FJ (2003) Paraoksonaz something more than an enzyme? Med Clin (Barc) 121:537–548

    Article  Google Scholar 

  9. Litvinov D, Mahini H, Garelnabi M (2012) Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci 4(11):523–532

    Article  PubMed  PubMed Central  Google Scholar 

  10. Aarsman AJ, Neys FW, Van den Bosch H (1991) Catabolism of platelet-activating factor and its acyl analog. Differentiation of the activities of lysophospholipase and platelet-activating-factor acetylhydrolase. Eur J Biochem 200:187–193

    Article  PubMed  CAS  Google Scholar 

  11. Koubaa N, Nakbi A, Smaoui M et al (2007) Hyperhomocysteinemia and elevated ox-LDL in Tunisian type 2 diabetic patients: role of genetic and dietary factors. Clin Biochem 40(13–14):1007–1014

    Article  PubMed  CAS  Google Scholar 

  12. Juretic D, Tadijanovic M, Rekic B, Simeon-Rudolf V, Reiner E, Baricic M (2001) Serum paraoxonase activities in hemodialyzed uremic patients: cohort study. Croat Med J 42:146–150

    PubMed  CAS  Google Scholar 

  13. Nakanishi M, Takanami Y, Maruyama T, Murata M, Motohashi Y, Nakano S, Uchida K, Maruyama C, Kyotani S, Tsushima M (2003) The ratio of serum paraoxonase/arylesterase activity using an improved assay for arylesterase activity to discriminate PON1(R192) from PON1(Q192). J Atheroscler Thromb 10(6):337–342

    Article  PubMed  CAS  Google Scholar 

  14. Taketo MM, Sonoshita M (2002) Phospholipase A2 and apoptosis. Biochim Biophys Acta 1585:72–76

    Article  PubMed  CAS  Google Scholar 

  15. Singh U, Zhong S, Xiong M, Li TB, Sniderman A, Teng BB (2004) Increased plasma non-esterified fatty acids and platelet-activating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice. Clin Sci (Lond) 106:421–432

    Article  CAS  Google Scholar 

  16. Cederholm A, Svenungsson E, Stengel D et al (2004) Platelet-activating factor acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 50:2869–2876

    Article  PubMed  CAS  Google Scholar 

  17. Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD (2006) PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin. Nephrol Dial Transpl 21:1270–1277

    Article  CAS  Google Scholar 

  18. Milionis HJ, Tambaki AP, Kanioglou CN, Elisaf MS, Tselepis AD, Tsatsoulis A (2005) Thyroid substitution therapy induces high-density lipoprotein-associated platelet activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect. Thyroid 15:455–460

    Article  PubMed  CAS  Google Scholar 

  19. Wan DH, Fan P, Bai H, Song Q, Liu HW (2010) Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance. Zhonghua Fu Chan Ke Za Zhi 45(1):30–34

    PubMed  CAS  Google Scholar 

  20. Bayrak T, Dursun P, Bayrak A, Gültekin M, Kolusarı A, Cakır E, Ozyurt M, Zeyneloğlu HB (2012) Paraoxonase lactonase activity (PON-HTLase), asymmetric dimethylarginine (ADMA) and platelet activating factor-acetylhydrolase (PAF-AH) activity in non-obese women with PCOS. Gynecol Endocrinol 28(11):874–878

    Article  PubMed  CAS  Google Scholar 

  21. Tosi F, Dorizzi R, Castello R et al (2009) Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome. Eur J Endocrinol 161(5):737–745

    Article  PubMed  CAS  Google Scholar 

  22. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, Katsilambros N, Kreatsas G, Panidis D (2006) Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 21:1426–1431

    Article  PubMed  CAS  Google Scholar 

  23. Jacobson TA (2013) Lipoprotein(a), cardiovascular disease, and contemporary management. Mayo Clin Proc 88(11):1294–1311

    Article  PubMed  CAS  Google Scholar 

  24. Hackenhaar FS, Martinez D, Medeiros TM et al (2012) Oxidized-LDL and paraoxonase-1 as biomarkers of coronary artery disease in patients with sleep-disordered breathing. Curr Med Chem 19(25):4359–4366

    Article  PubMed  CAS  Google Scholar 

  25. Murri M, Luque-Ramírez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF (2013) Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update 19(3):268–288

    Article  PubMed  CAS  Google Scholar 

  26. Dursun P, Demirtaş E, Bayrak A, Yarali H (2006) Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS? Hum Reprod 21(1):104–108

    Article  PubMed  CAS  Google Scholar 

  27. Bayram F, Kocer D, Ozsan M, Muhtaroglu S (2012) Evaluation of endothelial dysfunction, lipid metabolism in women with polycystic ovary syndrome: relationship of paraoxonase 1 activity, malondialdehyde levels, low-density lipoprotein subfractions, and endothelial dysfunction. Gynecol Endocrinol 28(7):497–501

    Article  PubMed  CAS  Google Scholar 

  28. Mohamadin AM, Habib FA, Elahi TF (2010) Serum paraoxonase 1 activity and oxidant/antioxidant status in Saudi women with polycystic ovary syndrome. Pathophysiology 17(3):189–196

    Article  PubMed  CAS  Google Scholar 

  29. Torun AN, Vural M, Cece H, Camuzcuoglu H, Toy H, Aksoy N (2011) Paraoxonase-1 is not affected in polycystic ovary syndrome without metabolic syndrome and insülin resistance, but oxidative stress is altered. Gynecol Endocrinol 27(12):988–992

    Article  PubMed  Google Scholar 

  30. Gupta N, Singh S, Maturu VN, Sharma YP, Gill KD (2011) Paraoxonase 1 (PON1) polymorphisms, haplotypes and activity in predicting CAD risk in North-West Indian Punjabis. PLoS One 6(5):e17805

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  31. Taşkiran P, Cam SF, Sekuri C, Tüzün N, Alioğlu E, Altintaş N, Berdeli A (2009) The relationship between paraoxanase gene Leu-Met (55) and Gln-Arg (192) polymorphisms and coronary artery disease. Turk Kardiyol Dern Ars 37(7):473–478

    PubMed  Google Scholar 

  32. Fortunato G, Rubba P, Panico S, Trono D, Tinto N, Mazzaccara C et al (2003) A paraoxonase gene polymorphism, PON 1 (55), as an independent risk factor for increased carotid intima-media thickness in middleaged women. Atherosclerosis 167:141–148

    Article  PubMed  CAS  Google Scholar 

  33. Regieli JJ, Jukema JW, Doevendans PA, Zwinderman AH, Kastelein JJ, Grobbee DE, van der Graaf Y (2009) Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. J Am Coll Cardiol 54(14):1238–1245

    Article  PubMed  CAS  Google Scholar 

  34. Balcerzyk A, Zak I, Krauze J (2007) Synergistic effects between Q192R polymorphism of paraoxonase 1 gene and some conventional risk factors in premature coronary artery disease. Arch Med Res 38(5):545–550

    Article  PubMed  CAS  Google Scholar 

  35. Birjmohun RS, Vergeer M, Stroes ES, Sandhu MS, Ricketts SL, Tanck MW, Wareham NJ, Jukema JW, Kastelein JJ, Khaw KT, Boekholdt SM (2009) Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk prospective population study. PLoS One 4(8):e6809

    Article  PubMed  PubMed Central  Google Scholar 

  36. Mendonça MI, Dos Reis RP, Freitas AI, Sousa AC, Pereira A, Faria P, Gomes S, Silva B, Santos N, Serrão M, Ornelas I, Freitas S, Araújo JJ, Brehm A, Cardoso AA (2008) Human paraoxonase gene polymorphisms and coronary artery disease risk. Rev Port Cardiol 27(12):1539–1555

    PubMed  Google Scholar 

  37. Likidlilid A, Akrawinthawong K, Poldee S, Sriratanasathavorn C (2010) Paraoxonase 1 polymorphisms as the risk factor of coronary heart disease in a Thai population. Acta Cardiol 65(6):681–691

    PubMed  Google Scholar 

  38. Campo S, Sardo MA, Trimarchi G, Bonaiuto M, Castaldo M, Fontana L, Bonaiuto A, Bitto A, Saitta C, Saitta A (2004) The paraoxonase promoter polymorphism (−107)T > C is not associated with carotid intima-media thickness in Sicilian hypercholesterolemic patients. Clin Biochem 37(5):388–394

    Article  PubMed  CAS  Google Scholar 

  39. Ehara S, Ueda M, Naruko T et al (2001) Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103:1955–1960

    Article  PubMed  CAS  Google Scholar 

  40. San Millan JL, Corton M, Villuendas G, Sancho J, Peral B, Ascobar-Morreale HF (2004) Association of polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab 89:2640–2646

    Article  PubMed  CAS  Google Scholar 

  41. San Millan JL, Alvarez-Blasco F, Luque-Ramirez M, Botella-Carretero JI, Ascobar-Morreale HF (2006) The PON1 −108C/T polymorphism, and not the polycystic ovary syndrome, is an important determinant of reduced serum paraoxonase activity in premenopausal women. Hum Reprod 21:3157–3161

    Article  PubMed  CAS  Google Scholar 

  42. Zhang F, Liu HW, Fan P, Bai H, Song Q (2011) The −108 C/T polymorphism in paraoxonase 1 gene in Chinese patients with polycystic ovary syndrome. Sichuan Da Xue Xue Bao Yi Xue Ban 42(1):24–28

    PubMed  CAS  Google Scholar 

  43. Wang Y, Liu H, Fan P, Bai H, Zhang J, Zhang F (2012) Evidence for association between paraoxonase 1 gene polymorphisms and polycystic ovarian syndrome in southwest Chinese women. Eur J Endocrinol 166(5):877–885

    Article  PubMed  CAS  Google Scholar 

  44. Lenarcik A, Bidzińska-Speichert B, Tworowska-Bardzińska U (2010) The role of chronic inflammation and Leu55Met PON1 polymorphism in the pathogenesis of polycystic ovary syndrome. Gynecol Endocrinol 26(9):673–683

    Article  PubMed  CAS  Google Scholar 

  45. Nishi K, Itabe H, Uno M et al (2002) Oxidised LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 22:1649–1654

    Article  PubMed  CAS  Google Scholar 

  46. Holvoet P, Van Cleemput J, Collen D, Vanhaecke J (2000) Oxidised low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 20:698–702

    Article  PubMed  CAS  Google Scholar 

  47. Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J (2000) Circulating oxidised low density lipoproteins levels. Arterioscler Thromb Vasc Biol 20:2243–2247

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by Fatih University Foundation.

Conflict of interest

No conflict of interest is present for each author.

Author information

Authors and Affiliations

  1. Department of Endocrinology, Regional Education and Research Hospital, Erzurum, Turkey

    Ayse Carlioglu

  2. Department of Obstetrics and Gynecology, Turgut Ozal University School of Medicine, Ciftlik Cad. No:57, Emek, 06510, Ankara, Turkey

    Ikbal Kaygusuz, Ilknur Inegol Gumus & Esra Aktepe Keskin

  3. Department of Endocrinıology, Gazi University Medical School, Ankara, Turkey

    Feridun Karakurt

  4. Department of Obstetrics and Gynecology, Education and Research Hospital, Antalya, Turkey

    Aysel Uysal

  5. Department of Internal Medicine, Turgut Ozal University Medical School, Ankara, Turkey

    Benan Kasapoglu

  6. Department of Biochemistry, Turgut Ozal University Medical School, Ankara, Turkey

    Ferah Armutcu

  7. Department of Biochemistry, Numune Education and Research Hospital, Ankara, Turkey

    Sema Uysal

  8. Department of Biochemistry, Atatürk Education and Research Hospital, Ankara, Turkey

    Cemile Koca

Authors
  1. Ayse Carlioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ikbal Kaygusuz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Feridun Karakurt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ilknur Inegol Gumus
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aysel Uysal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Benan Kasapoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ferah Armutcu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sema Uysal
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Esra Aktepe Keskin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Cemile Koca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ikbal Kaygusuz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Carlioglu, A., Kaygusuz, I., Karakurt, F. et al. The platelet activating factor acetyl hydrolase, oxidized low-density lipoprotein, paraoxonase 1 and arylesterase levels in treated and untreated patients with polycystic ovary syndrome. Arch Gynecol Obstet 290, 929–935 (2014). https://doi.org/10.1007/s00404-014-3275-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-014-3275-8

Keywords

Search

Navigation